Biotech - Spark Newswire

6 minute read

Sangamo Therapeutics Announces Evidence Of Clinical Benefit In Phase 1/2 STAAR Study In Fabry Disease

Today, 2:10 AM

- Sustained, elevated expression of alpha-galactosidase A (α-Gal A) activity observed in 13 patients for over two years for the longest treated patient as of cutoff

SGMO

3 minute read

Additional Interim Data From Phase I/II/III CAMPSIITE Trial Of REGENXBIO’s RGX-121 For The Treatment Of MPS II (Hunter Syndrome) Presented At 19th Annual WORLDSymposium

By Happy Mohamed

Today, 2:10 AM

RGX-121, a potential one-time gene therapy for the treatment of MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels Additional data from patients in Cohort 3 using pivotal program

RGNX

1 minute read

Analyst Sees Attractive Entry Opportunity After BioCryst’s Pipeline Setback

By Vandana Singh

Today, 2:10 AM

Tucked in its Q4 earnings press release, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported a setback on the early-stage BCX10013 study. The company…

BCRX

1 minute read

Immunocore Reveals First Data From HIV Infection Candidate Study

By Vandana Singh

Today, 2:10 AM

Immunocore Holdings plc (NASDAQ:IMCR) has presented the first safety and activity data with IMC-M113V, a bispecific soluble TCR therapy built on…

IMCR

3 minute read

Gilead Presents Proof-Of-Concept Data For Investigational Combination Regimen Of Lenacapavir With Broadly Neutralizing Antibodies As A Potential Twice-Yearly Approach For The Treatment Of HIV

By Happy Mohamed

Today, 2:10 AM

– Study Demonstrates the Potential of Lenacapavir in Combination with Broadly Neutralizing HIV Antibodies Teropavimab and Zinlirvimab – – Findings Support Further Evaluation of the Investigational

GILD

2 minute read

Co-Diagnostics, Inc. Initiates Clinical Evaluations For Its At-Home And Point-Of-Care Co-Dx PCR Home Platform

By Happy Mohamed

Today, 2:10 AM

Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced

CODX

2 minute read

Ovia Health Expands Digital Platform Capabilities To Include Menopause Tracking

By Happy Mohamed

Today, 2:10 AM

Digital platform expansion provides women access to resources for their unique health care needs Ovia Health, a trusted digital health platform for women and families, today announced the expansion of its Ovia® app,

2 minute read

Eterna Therapeutics Enters Into Option And License Agreement With Lineage Cell Therapeutics To Develop Hypoimmune Pluripotent Cell Lines For Multiple Neurology Indications

By Happy Mohamed

Today, 2:10 AM

Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna"), a preclinical-stage biotechnology company committed to realizing the potential of mRNA cell engineering to provide patients with transformational

ERNA

1 minute read

ProPhase Labs Announces Plans To Initiate Clinical Trial Of Equivir, Goal To Launch Commercially In Q4 2023

By Happy Mohamed

Today, 2:10 AM

ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase"), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly-owned subsidiary, ProPhase BioPharma, Inc. (PBIO), is

PRPH

1 minute read

Astrazeneca’s Tablet Formulation Of Calquence (Acalabrutinib) Has Been Approved In The European Union (Eu) For Adult Patients With Chronic Lymphocytic Leukemia.

By Benzinga Newsdesk

Today, 2:10 AM

The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use and is based on results from the ELEVATE-PLUS trials published in the American Society of

AZN